Purpose

A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized with COVID-19

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult patient (> 18 years of age) - Tested positive or person under investigation (PUI) for COVID-19 infection - Currently require heated high-flow oxygen therapy to maintain SaO2 > 90 % - Signed informed consent (phone consent) - Heated high-flow oxygen initiated within the past 72 hours

Exclusion Criteria

  • Serious medical condition that, in the investigator's judgment, precludes the patient's safe participation in the study - Pressure related risk for pneumothorax - Patient inability or unwillingness to tolerate OLE therapy - Staff unavailable or unable to deliver therapy - Current requirement for mechanical ventilation or expected requirement for mechanical ventilation within the next 12 hours

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
The active treatment group will consist of patients who are treated OLE therapy while on heated high-flow oxygen therapy. Results from subjects in the active treatment group will be compared to retrospectively collected results from patients treated with standard care with no OLE therapy.
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
OLE Therapy with The MetaNeb® System
Subjects in the active treatment group will receive OLE therapy with The MetaNeb® System following the labeled instructions for the device.
  • Device: MetaNeb® System
    The intervention device use in this study is The MetaNeb® System (Hill-Rom; St. Paul, MN). It is an FDA 510k cleared device (k124032), powered by compressed gas, that delivers oscillation and lung expansion (OLE) therapy using both continuous high-frequency oscillation (CHFO) and continuous positive expiratory pressure (CPEP). The device also provides supplemental oxygen when used with compressed oxygen and can deliver aerosol therapy during CPEP and/or CHFO. The therapy is indicated for mobilization of secretions, lung expansion therapy and the treatment and prevention of pulmonary atelectasis. The device also provides supplemental oxygen when used with compressed oxygen.
No Intervention
Control Group
The airway clearance regimen for subjects in the control group will be collected from the medical record.This information will be retrospectively collected from patients treated with standard care with no OLE therapy. Subjects in the control group will be identified from the population of patients previously admitted to the two study sites with COVID-19 infection who required invasive mechanical ventilation but were not treated with OLE therapy.

Recruiting Locations

Emory University
Atlanta, Georgia 30322
Contact:
Elizabeth Cox
elizabeth.m.cox@emory.edu

Northwestern University
Evanston, Illinois 60208
Contact:
Phill Cooper
312-503-0406
p-cooper@northwestern.edu

More Details

NCT ID
NCT04582214
Status
Unknown status
Sponsor
Hill-Rom

Study Contact

Brian Becker, RT
612.600.1301
brian.becker@hillrom.com

Detailed Description

This is a randomized prospective open-label cohort study in patients with COVID-19 to evaluate the impact of Oscillation and Lung Expansion (OLE) therapy using The MetaNeb® System on the hospital length of stay in patients hospitalized and receiving heated high-flow oxygen therapy for COVID-19 infection. The active treatment group will consist of patients who are treated OLE therapy while on heated high-flow oxygen therapy . Results from subjects in the active treatment group will be compared to results from patients treated with standard care with no OLE therapy.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.